Initial durability data shows all patients (100%) who completed the Maintenance Treatment Phase (MTP) sustained CRs in the treated area for at least 12 months as of the data cutoff date -- ...
On Monday, April 24, The Biotechnology Study Center of NYU School of Medicine will hold its annual awards symposium to honor three outstanding pioneers in neurobiology and cognition. The Dart/NYU ...
Teva Pharmaceutical Industries has announced the findings from the final analysis of the real-world pan-European PEARL Phase ...
Treatment with UBX1325 resulted in vision gains comparable to aflibercept at weeks 24 and 36 in difficult-to-treat patient population UBX1325 was non-inferior to aflibercept at week 24 (>90% ...
UNITY Biotechnology, Inc. has announced that it will present data from its ASPIRE Phase 2B study on its senolytic candidate, UBX1325, targeting diabetic macular edema at the upcoming ARVO 2025 Annual ...
TipRanks on MSN
MAIA Biotechnology Expands Phase 2 Study in Romania
MAIA Biotechnology, Inc. ( ($MAIA) ) has shared an announcement. On November 20, 2025, MAIA Biotechnology announced that its CEO, Vlad Vitoc, ...
NEW YORK -- Investors accurately forecasted the rebound of the biotechnology industry, but underestimated the degree to which positive clinical trial data would drive the sector higher, according to ...
On Tuesday, Sana Biotechnology Inc (NASDAQ:SANA) released the initial results from a first-in-human study transplanting UP421, an allogeneic primary islet cell therapy engineered with Sana’s ...
Unity Biotechnology, Inc. (NASDAQ:UBX) stock plummeted on Monday after the company released results from its latest study. The Phase 2b ASPIRE clinical trial of intravitreal UBX1325 involed patients ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback